The company has received $491 million in funding from several prominent technology and health science companies, strategic angel investors, and venture capital firms. Sequoia Capital led the most recent round of financing, which included investments from Fidelity Management & Research Company, Euclidean Capital, Altimeter Capital and the Wallenberg Foundation. Fidelity Management led the previous round of financing. Other 23andMe investors include Yuri Milner, Johnson & Johnson Development Corporation (NYSE: JNJ), MPM Capital, The Roche Venture Fund (Swiss: RO.SW ), Google Ventures (NASDAQ: GOOG),  New Enterprise Associates., Casdin Capital, WuXi Healthcare Ventures, Xfund, and Illumina (ILMN).